161 related articles for article (PubMed ID: 34666108)
1. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
Pacreau ML; Bomme O; Burrel S; Boutolleau D
Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
[TBL] [Abstract][Full Text] [Related]
2. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
3. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
Shiraki K; Yasumoto S; Toyama N; Fukuda H
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
[TBL] [Abstract][Full Text] [Related]
4. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
5. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
6. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment.
Shiraki K; Takemoto M; Daikoku T
Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1415-1425. PubMed ID: 33853490
[No Abstract] [Full Text] [Related]
7. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
Maeda H; Nakamura H; Kikukawa Y
Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
[TBL] [Abstract][Full Text] [Related]
9. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
[TBL] [Abstract][Full Text] [Related]
10. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
11. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
Katsumata K; Chono K; Suzuki H
Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Drugs Against Alphaherpesvirus.
Shiraki K
Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case.
Ishiguro A; Takama H; Yanagishita T; Ohshima Y; Watanabe D
J Dermatol; 2019 Aug; 46(8):e270-e271. PubMed ID: 30897230
[No Abstract] [Full Text] [Related]
14. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
15. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
16. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.
Andrei G; Snoeck R
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672709
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Chono K; Katsumata K; Suzuki H; Shiraki K
Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
[TBL] [Abstract][Full Text] [Related]
18. Drugs in development for herpes simplex and varicella zoster virus.
Birkmann A; Zimmermann H
Clin Pharmacol Ther; 2017 Jul; 102(1):30-32. PubMed ID: 28160282
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient.
Kobayashi H; Yoshida Y; Komoshita T; Suma H; Hosokawa Y; Hirose Y; Sugimoto T; Mokuda S; Hirata S; Sugiyama E
Intern Med; 2022 Jun; 61(11):1785-1788. PubMed ID: 34776482
[TBL] [Abstract][Full Text] [Related]
20. Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals.
Perrier M; Désiré N; Deback C; Agut H; Boutolleau D; Burrel S
J Virol Methods; 2016 Jul; 233():10-4. PubMed ID: 26994966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
